BioTuesdays

Category - Markets

Cellular Biomedicine Group
Markets

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

September 17, 2019
BioCardia
Markets

Dawson James starts BioCardia at buy; PT $24

Dawson James Securities launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $24 price target. The stock closed at $4.84 on Sept. 16. BioCardia is a developing two different cell therapy systems to...

September 17, 2019
Cellectar Biosciences
Markets

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...

September 13, 2019
Markets

BTIG ups Eidos Therapeutics PT to $56 from $38

BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to...

September 13, 2019
T2 Biosystems Logo
Markets

Analysts up T2 Biosystems price targets

Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...

September 12, 2019
AVEO Pharmaceuticals Logo
Markets

HCW ups AVEO Pharma to buy; PT to $1.75 from $1

H.C. Wainwright upgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “buy” from “neutral” and raised its price target to $1.75 from $1, citing a positive overall survival (OS) update from the Phase 3 TIVO-3 study of tivozanib...

September 11, 2019